Anesthetic and Analgesic Drug Products Advisory Committee
Stored: Anesthetic and Analgesic Drug Products Advisory Committee
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is part of the U.S. Food and Drug Administration (FDA) and advises on matters related to anesthetics, analgesics, and related drug products. Based in Silver Spring, Maryland, the committee reviews data and provides recommendations on drug safety, efficacy, and labeling.
Mission
The mission of AADPAC is to advise the FDA on the safety, effectiveness, and appropriate use of anesthetic and analgesic drugs. This includes reviewing new drug applications, discussing post-approval studies, and addressing public health concerns related to these medications, particularly in the context of pain management and anesthesia.[1]
Parent organization
AADPAC is part of the Food and Drug Administration (FDA), which falls under the Department of Health and Human Services. The FDA is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Legislation
While not established by a specific piece of legislation, AADPAC operates under the authority of the FDA, which is empowered by various acts like the Federal Food, Drug, and Cosmetic Act. Its activities are influenced by broader regulatory frameworks concerning drug regulation.
Partners
- Pharmaceutical companies for data submission and discussion
- Academic and research institutions for ongoing research collaboration
- Other FDA advisory committees for cross-disciplinary advice
Number of employees
The committee does not have permanent employees but consists of voting members, including experts in anesthesiology, analgesics, epidemiology, and consumer representatives.
Organization structure
AADPAC's structure includes:
Leader
The committee's proceedings are managed by the Designated Federal Officer (DFO).
Divisions
- No formal divisions; the committee operates as a single entity with members appointed based on expertise.
List of programs
- Regular meetings to review specific drug applications or broader issues like opioid abuse
- Subcommittees for preliminary evaluations (when necessary)
Last total enacted budget
Specific budget information for AADPAC is not publicly disclosed, as it is a part of the FDA's broader budgetary allocations.
Staff
Staffing for meetings includes the DFO and support from FDA staff; however, the committee itself is composed of external experts who serve in an advisory capacity.
Funding
Funding for AADPAC activities is part of the FDA's overall budget for advisory committee operations.
Services provided
AADPAC provides recommendations on drug approval, labeling, and post-marketing surveillance. It focuses on ensuring that anesthetic and analgesic drugs meet high standards of safety and effectiveness, particularly addressing issues like addiction, side effects, and drug interactions.[2]
Headquarters address
10903 New Hampshire Ave, Silver Spring, MD 20993
History
AADPAC was chartered to provide scientific and technical advice on drugs used in anesthesia and pain management. Its charter is regularly renewed, typically every two years, to continue its advisory role. The committee's history includes pivotal discussions on drug safety, particularly in the context of the opioid crisis and advancements in pain relief technologies.
External links
References
- ↑ Food and Drug Administration (2025). "Anesthetic and Analgesic Drug Products Advisory Committee". FDA.
- ↑ Food and Drug Administration (2025). "Human Drug Advisory Committees". FDA.